Bortezomib vs TQB3602
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Bortezomib
Marketed by Takeda Pharmaceutical Company and partners
NCT00048230 · Phase 3 · completed
APEX randomized 620 patients with relapsed multiple myeloma to bortezomib or high-dose dexamethasone in an open-label design. Its primary endpoint, time to progression, is a clinical outcome and was met. An open-label trial is never graded strong under the rubric, so the grade is moderate.
Next expected readout: November 2026 · NCT06505369 (registry estimate)
Reported efficacy
Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73 (met)
Result source: NCT00722566
TQB3602
Developed by Sino Biopharmaceutical
NCT04275583 · Phase 1 · status unknown
This is a small, open-label, single-arm, non-randomized dose-finding study designed to establish tolerability rather than to test clinical benefit, with no comparator arm and no blinding. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
These results cover the 25-patient dose-escalation phase; the study's dose-expansion phase is not included.
Reported efficacy
Dose-limiting toxicity (DLT) (Baseline up to 28 days): Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better.
Result source: NCT04275583
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bortezomib | TQB3602 |
|---|---|---|
| PFS, median | 11.2 vs 7.1vs BTZ+LD-DEXNCT0173492814 other results
| —Not reported |
| OS, median | 83.0 vs 53.6vs Velcade, Melphalan and PrednisoneNCT0219547910 other results
| —Not reported |
| ORR | 90.9% vs 73.9%vs Velcade, Melphalan and PrednisoneNCT0219547912 other results
| —Not reported |
| VGPR or better | 71.1% vs 49.7%vs Velcade, Melphalan and PrednisoneNCT021954798 other results
| —Not reported |
| MRD negativity | 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT036520645 other results
| —Not reported |
PFS, median
- Bortezomib
- 11.2 vs 7.1vs BTZ+LD-DEXNCT01734928
14 other results
- 13.9 vs 9.5 NCT03110562
- 46.7 NCT02541383
- 14.7 NCT00507416
- 15.4 NCT00507416
- 17.3 NCT00507416
- 36.4 vs 19.3 NCT02195479
- 6.6 vs 8.8 NCT03110562
- 22.5 vs 22.1 NCT01539083
- 3.9 vs 8.8 NCT03110562
- 9.9 vs 12.6 NCT00813150
- 52.8 NCT02541383
- 3.9 NCT03110562
- 8.1 vs 7.6 NCT00401843
- 15.3 NCT02290431
- TQB3602
- —Not reported
OS, median
- Bortezomib
- 83.0 vs 53.6vs Velcade, Melphalan and PrednisoneNCT02195479
10 other results
- 49.6 vs 38.5 NCT02136134
- 35.6 vs 31.6 NCT01734928
- 36.7 vs 32.8 NCT03110562
- 41.5 NCT00813150
- 30.8 NCT00103506
- 33 NCT00103506
- 49.8 NCT00507416
- 51.5 NCT00507416
- 53.1 NCT00507416
- 30.8 vs 36.8 NCT00401843
- TQB3602
- —Not reported
ORR
- Bortezomib
- 90.9% vs 73.9%vs Velcade, Melphalan and PrednisoneNCT02195479
12 other results
- 82.9% vs 63.2% NCT02136134
- 76.4% vs 62.3% NCT03110562
- 70.2% vs 74.4% NCT00813150
- 19% NCT03110562
- 73% NCT00507416
- 80% NCT00507416
- 70% NCT00507416
- 88.1% NCT03412565
- 90.8% NCT03412565
- 55% vs 46.7% NCT00401843
- 80.6% NCT02290431
- 97% NCT03412565
- TQB3602
- —Not reported
VGPR or better
- Bortezomib
- 71.1% vs 49.7%vs Velcade, Melphalan and PrednisoneNCT02195479
8 other results
- 59.2% vs 29.1% NCT02136134
- 44.6% vs 32.4% NCT03110562
- 37% NCT00507416
- 51% NCT00507416
- 41% NCT00507416
- 71.6% NCT03412565
- 77.6% NCT03412565
- 80% NCT03412565
- TQB3602
- —Not reported
MRD negativity
- Bortezomib
- 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT03652064
5 other results
- 60.9% vs 39.4% NCT03652064
- 28.3% vs 7% NCT02195479
- 13.5% vs 2.8% NCT02136134
- 25.4% NCT03412565
- 21.5% NCT03412565
- TQB3602
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Bortezomib: 4 of 4 rows · TQB3602: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bortezomib |
|---|---|
| Dropout rate | 47.3%VELCADE Intravenousa NCT00722566 · Phase 3 show 32 more results45.3%VELCADE Subcutaneous NCT00722566 · Phase 3 n/a: no completion milestone NCT03652064 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02195479 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 1.1%Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneSVd Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 15%Arm A: VELCADE, CYCLOPHOSPHAMIDE, NCT01146834 · Phase 3 · registry result, not featured evidence 0%Arm B: VELCADE & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination 0% NCT01109004 · Phase 3 · registry result, not featured evidence 20.7%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneDoxil/Caelyx Plus Velcade (Bortezo NCT00103506 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneVelcade (Bortezomib) Monotherapy NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy 70.2%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 68.3%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 74.9%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 68.1% NCT00813150 · Phase 3 · registry result, not featured evidence · combination 64.3% NCT01801436 · Phase 3 · registry result, not featured evidence 71.6%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination 1.5%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination 78.5%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination 15.4% NCT02874742 · Phase 2 · registry result, not featured evidence · combination 0% NCT02703779 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePart 1 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePart 2 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 87.1% NCT02290431 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —VELCADE Intravenousa NCT00722566 · Phase 3 show 32 more results—VELCADE Subcutaneous NCT00722566 · Phase 3 — NCT03652064 · Phase 3 · registry result, not featured evidence — NCT02195479 · Phase 3 · registry result, not featured evidence · combination — NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination —Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 0.5%SVd Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Arm A: VELCADE, CYCLOPHOSPHAMIDE, NCT01146834 · Phase 3 · registry result, not featured evidence —Arm B: VELCADE & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination — NCT01109004 · Phase 3 · registry result, not featured evidence 5.5%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Doxil/Caelyx Plus Velcade (Bortezo NCT00103506 · Phase 3 · registry result, not featured evidence · combination —Velcade (Bortezomib) Monotherapy NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy 34.5%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 38.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 40.1%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 31.9% NCT00813150 · Phase 3 · registry result, not featured evidence · combination 14.3% NCT01801436 · Phase 3 · registry result, not featured evidence —D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination —Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination —Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination — NCT02874742 · Phase 2 · registry result, not featured evidence · combination — NCT02703779 · Phase 2 · registry result, not featured evidence 33.3%Part 1 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 19%Part 2 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 64.5% NCT02290431 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 35.1%VELCADE Intravenousa NCT00722566 · Phase 3 show 32 more results36.1%VELCADE Subcutaneous NCT00722566 · Phase 3 72.1% NCT03652064 · Phase 3 · registry result, not featured evidence 53.8% NCT02195479 · Phase 3 · registry result, not featured evidence · combination 55.1% NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 49.3%DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination 18.8%DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 27.5%VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 63.7%Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination —Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 55.9%SVd Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 42.4%SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0%Arm A: VELCADE, CYCLOPHOSPHAMIDE, NCT01146834 · Phase 3 · registry result, not featured evidence 0%Arm B: VELCADE & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination 20.6% NCT01109004 · Phase 3 · registry result, not featured evidence 34.6%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination 27.2%Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination 37.7%Doxil/Caelyx Plus Velcade (Bortezo NCT00103506 · Phase 3 · registry result, not featured evidence · combination 33%Velcade (Bortezomib) Monotherapy NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy 53.3%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 50.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 58.2%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 29.8% NCT00813150 · Phase 3 · registry result, not featured evidence · combination 100% NCT01801436 · Phase 3 · registry result, not featured evidence 44.8%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination 28.4%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination 56.9%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination 46.5% NCT02874742 · Phase 2 · registry result, not featured evidence · combination 48% NCT02703779 · Phase 2 · registry result, not featured evidence 47.6%Part 1 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 33.1%Part 2 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 45.2% NCT02290431 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 29 more resultsdiarrhoea 56.3% peripheral sensory neuropathy 55.8% neutropenia 54.8% NCT03652064 · Phase 3 · registry result, not featured evidence neutropenia 50.3% thrombocytopenia 49.7% anaemia 31.8% NCT02195479 · Phase 3 · registry result, not featured evidence · combination thrombocytopenia 59.7% peripheral sensory neuropathy 50.2% diarrhoea 36.2% NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 peripheral sensory neuropathy 60.6% constipation 50.6% asthenia 32.8% NCT02541383 · Phase 3 · registry result, not featured evidence · combination bronchitis 40.6% cough 17% nasopharyngitis 17% NCT02541383 · Phase 3 · registry result, not featured evidence bronchitis 36.5% cough 19.4% nasopharyngitis 17.5% NCT02541383 · Phase 3 · registry result, not featured evidence neutropenia 54% peripheral sensory neuropathy 48.2% thrombocytopenia 39.6% NCT01734928 · Phase 3 · registry result, not featured evidence · combination thrombocytopenia 61.5% nausea 50.3% fatigue 42.1% NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 thrombocytopenia 50% anaemia 45.5% nausea 39.4% NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 anemia 40% nausea 35% platelet count decreased 35% NCT01146834 · Phase 3 · registry result, not featured evidence platelet count decreased 100% anemia 50% generalized muscle weakness 50% NCT01146834 · Phase 3 · registry result, not featured evidence constipation 35.8% nausea 32.3% peripheral sensory neuropathy 24.4% NCT01539083 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 37.9% peripheral sensory neuropathy 36.9% neuropathy peripheral 29.1% NCT01539083 · Phase 3 · registry result, not featured evidence · combination nausea 47.8% diarrhoea 44.7% fatigue 36.2% NCT00103506 · Phase 3 · registry result, not featured evidence · combination nausea 39.3% diarrhoea 38.4% constipation 30.8% NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy insomnia 5.5% weight decreased 2.4% blood sodium decreased 1.8% NCT00507416 · Phase 3 · registry result, not featured evidence · combination leukopenia 7.4% platelet count decreased 4.3% insomnia 3.7% NCT00507416 · Phase 3 · registry result, not featured evidence · combination hyperuricaemia 5.1% insomnia 3.8% cough 3.2% NCT00507416 · Phase 3 · registry result, not featured evidence · combination fatigue 38.3% thrombocytopenia 38.3% diarrhoea 36.2% NCT00813150 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 78.6% white blood cell count decreased 78.6% platelet count decreased 71.4% NCT01801436 · Phase 3 · registry result, not featured evidence thrombocytopenia 56.7% anaemia 44.8% constipation 44.8% NCT03412565 · Phase 2 · registry result, not featured evidence · combination peripheral sensory neuropathy 41.8% constipation 38.8% neutropenia 37.3% NCT03412565 · Phase 2 · registry result, not featured evidence · combination neutropenia 67.7% diarrhoea 49.2% anaemia 40% NCT03412565 · Phase 2 · registry result, not featured evidence · combination fatigue 71.7% upper respiratory tract infection 67.7% diarrhoea 65.7% NCT02874742 · Phase 2 · registry result, not featured evidence · combination diarrhea 58% (placebo 56.9%) nausea 58% (placebo 64.7%) anorexia 54% (placebo 51%) NCT02703779 · Phase 2 · registry result, not featured evidence neutropenia 81% (placebo 38.1%) diarrhoea 61.9% (placebo 36%) thrombocytopenia 61.9% (placebo 46.8%) NCT00401843 · Phase 2 · registry result, not featured evidence · combination neutropenia 60.6% (placebo 38.1%) thrombocytopenia 58.5% (placebo 46.8%) peripheral sensory neuropathy 51.4% (placebo 52.5%) NCT00401843 · Phase 2 · registry result, not featured evidence · combination diarrhoea 80.6% decreased appetite 58.1% thrombocytopenia 54.8% NCT02290431 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 30 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bortezomib
show 1 more result
show 4 more results
show 3 more results
show 10 more results
show 4 more results
show 2 more results
show 5 more results
show 7 more results
show 3 more results
show 2 more results
+ 54 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bortezomib's landscape · TQB3602's landscape